Trial intelligence / Profile preview

Azacitidine with or without low-dose dasatinib for maintenance treatment of acute myeloid leukemia

ChiCTR2100042418Phase 4Recruiting

Sponsor
The First Hospital of Lanzhou University
Start
Dec 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of azacitidine and dasatinib in acute myeloid leukemia (AML) (2 arms), sponsored by The First Hospital of Lanzhou University. Primary endpoints: Overall survival and Disease-free survival. Started Dec 2020; status: recruiting.

02

Drugs

azacitidinedasatinib
03

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on ChiCTR2100042418.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100042418.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call